Gilead Sciences Hellas Μ.EPE

2 Rizountos & Thrakis Str.
167 77 Helliniko, Athens

Phone: +30 210 89 30 100 
Fax: +30 210 96 18 260

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Gilead Hellas has been operating in Greece since December 1995. It was first established as NeXstar Pharmaceuticals Inc. and subsequently became Gilead Sciences Hellas M.EPE in 2001. Gilead's office in Athens provides sales, marketing, regulatory and medical support for our products throughout Greece and the Middle East.

Relationships with Charitable Organizations

Gilead provided support for the following charitable organizations in 2013, via unrestricted educational grants. The information is correct at the time of writing (March 2014). The information is subject to change and will be updated accordingly.

  • Grant Recipient
    Description of Activity
    Amount Funded €
  • PROMETHEUS (Hellenic Liver Patients Association)
    Supporting awareness projects and initiatives of PROMETHEUS.
  • Positive Voice
    Supporting  awareness & educational projects on HIV ( HIV and Your Body/January-September 2013. Athens & Thessaloniki).
  • Positive Voice
    Athens Checkpoint, an important HIV testing initiative
  • PROMETHEUS (Hellenic Liver Patients Association)
    Supporting  awareness projects and initiatives during the World Hepatitis Day (17-21 June 2013).
  • Hellenic Cystic Fibrosis Association
    Supporting an Awareness Campaign for the  Cystic Fibrosis
  • PROMETHEUS (Hellenic Liver Patients Association)
    Supporting an Awareness Campaign regarding Hepatitis C (Oct 2013-Dec 2014)
  • Cystic Fibrosis Patients Organization
    Supporting  activities during the European Week for the Cystic Fibrosis
  • Positive Voice
    Thessaloniki Checkpoint (ThessCheckpoint), an important HIV testing initiative.
Language: Ελληνικά

This page is intended for visitors outside of the United States.